David P. Carbone

46.2k citations

413 papers · 26.9k indexed · 12 hit papers · h-index 78

Impact in

Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer

Papers in

Oncology 218
- Cancer Immunotherapy and Biomarkers 76
- Lung Cancer Research Studies 63
- Colorectal Cancer Treatments and Studies 24
Cancer Research 102
- Cancer Genomics and Diagnostics 66

Co-authors: Dmitry I. Gabrilovich Sorena Nadaf Tsunehiro Oyama Tadao Ishida Sophia Ran Joyce E. Ohm Yu Shyr Vladimir Kravtsov
Journals: Journal of Clinical Oncology (75 papers)Journal of Thoracic Oncology (48 papers)Cancer Research (24 papers)Lung Cancer (22 papers)Annals of Oncology (13 papers)
Partner nations: United States Japan Germany

In The Last Decade

David P. Carbone

404 papers receiving 26.4k citations

Hit Papers

12 papers align trajectories log scale

Recent advances in therapeutic strategies for non-small cell lung cancer 2025 · 15 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 Journal of Hematology & Oncology
2021 Annals of Oncology
2015 JNCI Journal of the National Cancer Institute
2015 Nature Reviews Disease Primers
2008 Cancer Cell
2004 Cancer Cell
2001 The Journal of Immunology
2000 Nature Immunology
2000 PubMed
1998 Blood
1998 Blood
1996 Nature Medicine

Peers

Countries citing papers authored by David P. Carbone

Since Specialization

Citations

This map shows the geographic impact of David P. Carbone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David P. Carbone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David P. Carbone more than expected).

Fields of papers citing papers by David P. Carbone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David P. Carbone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David P. Carbone. The network helps show where David P. Carbone may publish in the future.

Co-authors

The 25 scholars most cited alongside David P. Carbone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David P. Carbone Line = papers co-authored together David P. Carbone links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Calls to action on lung cancer management and research The Oncologist ·Iulia Enachescu, Fred R. Hirsch, Paul A. Bunn, Peter Ujházy, Amy C. Blake, Christine D. Berg, David P. Carbone, Balázs Halmos, Harpreet Singh, Hossein Borghaei, Andrea Ferris, Corey J. Langer, Sanja Đačić, Tony Mok, Solange Peters, Bruce E. Johnson	2024	1
2	STK11/LKB1 Loss of Function Is Associated with Global DNA Hypomethylation and S -Adenosyl-Methionine Depletion in Human Lung Adenocarcinoma Cancer Research ·Michael J. Koenig, Juliana Pandino Leonardo Peixoto, Jacob M. Kaufman, Victoria Ozga, Walter Wang, Christoph Weigel, Fábio C. P. Navarro, Joseph M. Amann, Yujian Qiang, Rajeswara Rao Arasada, Mark Gerstein, Vicki H. Wysocki, Christopher C. Oakes, David P. Carbone	2021	10
3	Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation Clinical Cancer Research ·Victoria E. Wang, Jenny Y. Xue, Dennie T. Frederick, Yi Cao, Eva Lin, Catherine Wilson, Anatoly Urisman, David P. Carbone, Keith T. Flaherty, René Bernards, Piro Lito, Jeff Settleman, Frank McCormick	2019	37
4	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study Clinical Cancer Research ·Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Dávila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone	2019	229
5	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations Molecular Cancer Therapeutics ·Tadaaki Yamada, Joseph M. Amann, Azusa Tanimoto, Hirokazu Taniguchi, Takehito Shukuya, Cynthia Timmers, Seiji Yano, Konstantin Shilo, David P. Carbone	2017	31
6	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma Cancer Research ·Jacob M. Kaufman, Tadaaki Yamada, Kyungho Park, Cynthia Timmers, Joseph M. Amann, David P. Carbone	2016	19
7	Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy Cancer Research ·奥山虎之, C. Starren, Roman V. Uzhachenko, Kyungho Park, Anwari Akhter, Rajeswara Rao Arasada, Jason V. Evans, Sergey V. Novitskiy, Elena E. Tchekneva, David P. Carbone, Anil Shanker, Mikhail M. Dikov	2015	46
8	SMARCA4 /BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer Clinical Cancer Research ·Erica H. Bell, Arup R. Chakraborty, Xiaokui Mo, Ziyan Liu, Konstantin Shilo, Simon Kirste, Petra Stegmaier, Maureen McNulty, Niki Karachaliou, Rafael Rosell, Gerold Bepler, David P. Carbone, Arnab Chakravarti	2015	115
9	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma Cancer Research ·Tadaaki Yamada, Joseph M. Amann, Koji Fukuda, Shinji Takeuchi, Naoya Fujita, Hisanori Uehara, Shotaro Iwakiri, Kazumi Itoi, Konstantin Shilo, Seiji Yano, David P. Carbone	2015	17
10	EGFR Blockade Enriches for Lung Cancer Stem–like Cells through Notch3-Dependent Signaling Cancer Research ·Rajeswara Rao Arasada, Joseph M. Amann, Mohammad Aminur Rahman, Stacey S. Huppert, David P. Carbone	2014	91
11	Genomic Characterization of Non-Small Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing International Journal of Radiation OncologyBiologyPhysics ·Luiz H. Araujo, Cynthia Timmers, Muhammad Khristamto Aditya Wardana, Gnananjali Gnanandan, Thanemozhi G. Natarajan, Jibin Zhang, Konstantin Shilo, Weiqiang Zhao, Joseph M. Amann, Philip E. Lammers, David P. Carbone	2014	3
12	Smoking Attenuates Transforming Growth Factor-β–Mediated Tumor Suppression Function through Downregulation of Smad3 in Lung Cancer Cancer Prevention Research ·Debangshu Samanta, Adriana L. Gonzalez, Nagaraj S. Nagathihalli, Fei Ye, David P. Carbone, Pran K. Datta	2012	29
13	Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules Cancer Epidemiology Biomarkers & Prevention ·Chad V. Pecot, Ming Li, А. М. ТЕРЕЗА, Darren Ezar, 黄梦婷, Aaron O. Bungum, James R. Jett, Joe B. Putnam, Carol Callaway‐Lane, Qunli Xia, Eric L. Grogan, David P. Carbone, John A. Worrell, Karel G.M. Moons, Yu Shyr, Pierre P. Massion	2012	45
14	Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth Cancer Research ·Yuhui Huang, Luping Lin, Anil Shanker, Anshu Malhotra, Li Yang, Mikhail M. Dikov, David P. Carbone	2011	62
15	Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions Cancer Research ·S.M. Jamshedur Rahman, Adriana L. Gonzalez, Ming Li, Erin H. Seeley, Lisa J. Zimmerman, А. М. ТЕРЕЗА, M. Lisa Manier, Sandra J. Olson, L. WALLIN, Michelle A. Marcus, Joe B. Putnam, York E. Miller, Wilbur A. Franklin, William J. Blot, David P. Carbone, Yu Shyr, Richard M. Caprioli, Pierre P. Massion	2011	59
16	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients Cancer Epidemiology Biomarkers & Prevention ·Christine H. Chung, Erin H. Seeley, Heinrich Röder, Julia Grigorieva, Maxim Tsypin, C Solbach, Barbara Burtness, Athanassios Argiris, Arlene A. Forastiere, Jill Gilbert, Barbara A. Murphy, Richard M. Caprioli, David P. Carbone, Ezra E.W. Cohen	2010	51
17	Inhibition of Epidermal Growth Factor Receptor Signaling Elevates 15-Hydroxyprostaglandin Dehydrogenase in Non–Small-Cell Lung Cancer Cancer Research ·Li Yang, Joseph M. Amann, Takefumi Kikuchi, Rut Porta, Marta Guix, Adriana González, Ki Hun Park, Dean Billheimer, Carlos L. Arteaga, Hsin-Hsiung Tai, Raymond N. DuBois, David P. Carbone, David H. Johnson	2007	50
18	Selective Profiling of Proteins in Lung Cancer Cells from Fine-Needle Aspirates by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry Clinical Cancer Research ·Joseph M. Amann, Pierre Chaurand, Adriana González, James A. Mobley, Pierre P. Massion, David P. Carbone, Richard M. Caprioli	2006	34
19	Thioredoxin-1 Modulates Transcription of Cyclooxygenase-2 via Hypoxia-Inducible Factor-1α in Non–Small Cell Lung Cancer Cancer Research ·Ildiko Csiki, Kiyoshi Yanagisawa, Nobuhiro Haruki, Sorena Nadaf, Jason D. Morrow, David H. Johnson, David P. Carbone	2006	79
20	Mutant Oncopeptide Immunization Induces CTL Specifically Lysing Tumor Cells Endogenously Expressing the Corresponding Intact Mutant p53 Hybridoma ·I. Frank Ciernik, Đinh Phương Hoa, David P. Carbone	1995	13

About David P. Carbone

David P. Carbone is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Biotechnology, having authored 413 papers that have together received 26.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (152 papers), Cancer Immunotherapy and Biomarkers (76 papers), Cancer Genomics and Diagnostics (66 papers), Lung Cancer Research Studies (63 papers), Immunotherapy and Immune Responses (49 papers), Lung Cancer Diagnosis and Treatment (46 papers), RNA modifications and cancer (28 papers) and Colorectal Cancer Treatments and Studies (24 papers). The work is most often cited by research in Oncology (13.6k citations), Immunology (9.1k citations), Cancer Research (4.5k citations), Pulmonary and Respiratory Medicine (6.5k citations) and Molecular Biology (10.9k citations). David P. Carbone has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Dmitry I. Gabrilovich, Sorena Nadaf, Tsunehiro Oyama, Tadao Ishida, Sophia Ran, Joyce E. Ohm, Yu Shyr, Vladimir Kravtsov, Joseph I. Clark and Bond Almand. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer Research, Lung Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact